Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..
2026.
Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..
2026.
Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..
2026.
Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.
Kent A, Mon KJoy Yee, Hutchins Z, Putzel G, Zhigarev D, Grier A, Jia B, Kortlever RM, Barbet G, Evan GI et al..
2025.
A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis.. Nat Immunol. 26(1):53-67.